1. Scrip
  2. >>Business

Advinus Ex-CEO's Bitter-Sweet Journey And Lessons Learnt

 
• By Anju Ghangurde

Life appears to have come full circle for Advinus Therapeutics' co-founder and former CEO and managing director, Dr Rashmi Barbhaiya, who recently moved back to the US from India. And it has been a bitter-sweet journey, replete with some peaks and troughs, although the man himself would rather term any lows as "lessons learned" that come with the territory.

"It is with mixed feelings I have returned to US after relentless pursuit of 14 years. I do want to keep the reins of my destiny in my hand," Barbhaiya, who began his industrial pharmaceutical career in 1980 with Bristol-Myers Squibb Co.in the US, told Scrip in an interview. He also lamented the limited understanding of investors in India of pharma R&D, but more on that later.

Barbhaiya, who was born in India, returned to the country from the US in 2002 to take charge as president...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.